Bionano Genomics Inc - Asset Resilience Ratio
Bionano Genomics Inc (BNGO) has an Asset Resilience Ratio of 13.95% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bionano Genomics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Bionano Genomics Inc's Asset Resilience Ratio has changed over time. See BNGO total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bionano Genomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bionano Genomics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.27 Million | 13.95% |
| Total Liquid Assets | $10.27 Million | 13.95% |
Asset Resilience Insights
- Moderate Liquidity: Bionano Genomics Inc has 13.95% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Bionano Genomics Inc Industry Peers by Asset Resilience Ratio
Compare Bionano Genomics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for Bionano Genomics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Bionano Genomics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.95% | $10.27 Million | $73.58 Million | +13.56pp |
| 2024-12-31 | 0.39% | $302.00K | $76.67 Million | -22.38pp |
| 2023-12-31 | 22.77% | $48.82 Million | $214.40 Million | -12.38pp |
| 2022-12-31 | 35.15% | $108.09 Million | $307.50 Million | -24.79pp |
| 2021-12-31 | 59.94% | $226.04 Million | $377.10 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $60.45 Million | -- |
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It als… Read more